

## EQA round: IDDM1/24 - Type 1 Autoimmune Diabetes

Deadline: 8.3.2024

Setup: groups - M (measurement principle)

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessed

CVP = consensus of all participants

N<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

&gt;&gt;&gt; ... expected result

S<sub>rel</sub> = relative success

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
<b>(472) anti-GAD</b>		33				0		
<b>Sample A</b>		33			33	33	100	
(2) EIA methods	CVP >>>	25	76	Positive				
(3) RIA, IRMA	CVP >>>	2	6,1	Positive				
(4) Luminiscence	CVP >>>	4	12	Positive				
(99) Another measurement principle	CVP >>>	2	6,1	Positive				
<b>Sample B</b>		33				0		
(2) EIA methods	±	25	76	Positive				
(3) RIA, IRMA	±	2	6,1	Negative				
(4) Luminiscence	±	4	12	Negative				
(99) Another measurement principle	±	2	6,1	Negative				
<b>(474) anti-IA-2</b>		30			30	29	97	
<b>Sample A</b>		30			30	29	97	
(2) EIA methods	CVP >>>	23	77	Positive				
(3) RIA, IRMA		1	3,3	Negative				
(4) Luminiscence	CVP >>>	4	13	Positive				
(99) Another measurement principle	CVP >>>	2	6,7	Positive				
<b>Sample B</b>		30			30	30	100	
(2) EIA methods	CVP >>>	23	77	Negative				
(3) RIA, IRMA	CVP >>>	1	3,3	Negative				
(4) Luminiscence	CVP >>>	4	13	Negative				
(99) Another measurement principle	CVP >>>	2	6,7	Negative				